Samarium-153

Pain

Radiation Therapy Oncology GroupradiopharmaceuticalPhase 3Dormant

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 81/ 100

Competitive context

44 Active assets in the Pain cohort.

Asset / Sponsor	Phase	Rating
NEPENTHE Bursa City Hospital	Phase 4	BBB
Oxycodone The First Affiliated Hospital with Nanjing Medical University	Phase 4	BBB
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Tapentadol Grünenthal GmbH	Phase 4	BBB
FENTANYL Aga Khan University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Samarium-153 is also rated in:

prostate cancerDormant

B

Indicative ·

56 / 100

metastatic malignant neoplasmDormant

B

Indicative ·

56 / 100

lung cancerDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.